Contraindicated (1)bortezomib will boost the stage or influence of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may possibly increase mavacamten systemic exposure, resulting in coronary heart failure as a result of systolic dysfunction. This medication is used to deal with specific varieties of most https://yogie433rcn6.blogvivi.com/profile